All Stories

  1. Localized Changes in Dentate Nucleus Shape and Magnetic Susceptibility in Friedreich Ataxia
  2. Expert consensus recommendations for improving and standardising the assessment of patients with generalised myasthenia gravis
  3. Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy
  4. Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta‐analysis and network meta‐analysis
  5. Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence
  6. The C-Terminal Cross-linked Telopeptide of Type I Collagen (CTX-I) as a Potential Cardiomyopathy Biomarker in Friedreich Ataxia Patients
  7. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
  8. Interplay Between Cognitive and Bowel/Bladder Function in Multiple Sclerosis
  9. A real‐world study of alemtuzumab in a cohort of Italian patients
  10. Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy
  11. First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study
  12. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study
  13. Is antibody titer useful to verify the immunization after VZV Vaccine in MS patients treated with Fingolimod? A case series
  14. The use of medical grade cannabis in Italy for drug-resistant epilepsy: a case series
  15. The complex phenotype of spinocerebellar ataxia type 48 in eight unrelated Italian families
  16. Overt hypogonadism may be not a sentinel sign of RNF216 : two novel mutations associated with ataxia, chorea and fertility
  17. Olfactory function and cognition in relapsing–remitting and secondary-progressive multiple sclerosis
  18. Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis
  19. Cognitive and functional connectivity alterations in Friedreich's ataxia
  20. Dissociative identity disorder: Restoration of executive functions after switch from alter to host personality
  21. Peripheral markers of autophagy in polyglutamine diseases
  22. The Multiple Faces of Spinocerebellar Ataxia type 2
  23. Normalization of timed neuropsychological tests with the PATA rate and nine-hole pegboard tests
  24. The iEDSS: BICAMS for the Cerebral Functional Score
  25. Lamivudine and fingolimod co-administration in two patients with multiple sclerosis and occult hepatitis B virus infection
  26. The use of medical-grade cannabis in patients non-responders to Nabiximols
  27. Mobitz type I and II atrioventricular blocks during fingolimod therapy
  28. Long-term effect of epoetin alfa on clinical and biochemical markers in friedreich ataxia
  29. Modifications of resting state networks in spinocerebellar ataxia type 2
  30. Multiple hormone deficiencies in chronic heart failure
  31. The combined use of conventional MRI and MR spectroscopic imaging increases the diagnostic accuracy in amyotrophic lateral sclerosis
  32. A randomized controlled pilot trial of lithium in spinocerebellar ataxia type 2
  33. Screening for dopa-responsive dystonia in patients with scans without evidence of dopaminergic deficiency (SWEDD)
  34. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial
  35. Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia
  36. Genetic Screening for the LRRK2 R1441C and G2019S Mutations in Parkinsonian Patients from Campania
  37. A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis
  38. A Randomized, Double-blind, Placebo-Controlled Study of Latrepirdine in Patients With Mild to Moderate Huntington Disease
  39. Migraine attack restores the response of vascular smooth muscle cells to nitric oxide but not to norepinephrine
  40. Clinical use of frataxin measurement in a patient with a novel deletion in the FXN gene
  41. A randomized clinical trial of lithium in multiple system atrophy
  42. A gene expression phenotype in lymphocytes from friedreich ataxia patients
  43. A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results
  44. A Combined Nucleic Acid and Protein Analysis in Friedreich Ataxia: Implications for Diagnosis, Pathogenesis and Clinical Trial Design
  45. Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit
  46. Benign hereditary chorea: Clinical and neuroimaging features in an Italian family
  47. Vascular smooth muscle cell dysfunction in patients with migraine
  48. SCA Functional Index: A useful compound performance measure for spinocerebellar ataxia
  49. Recombinant Human Erythropoietin Increases Frataxin Protein Expression Without Increasing mRNA Expression
  50. Ataxia with oculomotor apraxia type 2: A clinical, pathologic, and genetic study
  51. Novel mutation ofSACSgene in a Spanish family with autosomal recessive spastic ataxia
  52. Autosomal recessive progressive myoclonus epilepsy with ataxia and mental retardation
  53. Very late onset in ataxia oculomotor apraxia type I